Showing results (81-90 of 106) with videos related to
Sort By:
Pageof 11
Blood Advances|September 1, 2021
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myelomaLuciano J Costa, Faith E Davies, Gregory P Monohan, et al.Research Square|July 3, 2023
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysisJulie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.Blood|July 27, 2018
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLAmir T Fathi, Harry P Erba, Jeffrey E Lancet, et al.Blood|December 3, 2017
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemiaEytan M Stein, Roland B Walter, Harry P Erba, et al.Leukemia|March 19, 2014
Functional integration of acute myeloid leukemia into the vascular nicheChristopher R Cogle, Devorah C Goldman, Gerard J Madlambayan, et al.Current Oncology (Toronto, Ont.)|March 26, 2025
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced MelanomaJulie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.Blood|April 4, 2020
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDAGiovanni Palladini, Efstathios Kastritis, Mathew S Maurer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialStefan Faderl, Meir Wetzler, David Rizzieri, et al.Seminars in Oncology|November 16, 2010
Signaling through OX40 enhances antitumor immunityShawn M Jensen, Levi D Maston, Michael J Gough, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 6, 2010
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignanciesEneida R Nemecek, Katherine A Guthrie, Mohamed L Sorror, et al.Pageof 11